Krill Oil for Triglycerides: What a 520-Patient Trial Actually Found
Educational summary — not medical advice. This is not a treatment for high triglycerides or any diagnosed condition; severely elevated triglycerides need a doctor's care. This statement has not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease.
The honest answer
Real, significant, and easy to misread. A pooled analysis of two randomized trials (n=520, JAMA Network Open) found a krill-derived agent lowered triglycerides 26.0% versus 15.1% for placebo at 12 weeks — a net -10.9% difference (p=0.02), sustained to 26 weeks (Mozaffarian 2022, TRILOGY). But the agent tested was a concentrated pharmaceutical-track product dosed at 4g/day in patients with severe hypertriglyceridemia — not the 1-2 softgel retail dose or the general population most krill oil buyers represent. Funded by Acasti Pharma, the agent's manufacturer.
The trial, read carefully
TRILOGY pooled two randomized, placebo-controlled trials (TRILOGY 1 and TRILOGY 2) testing CaPre, an omega-3 phospholipid/free-fatty-acid agent derived from krill, manufactured by Acasti Pharma. All 520 participants had severe hypertriglyceridemia at baseline. The dose was 4 grams per day for 26 weeks. The primary result: triglycerides fell 26.0% (95% CI 20.5-31.5%) in the treatment group versus 15.1% (95% CI 6.6-23.5%) with placebo at 12 weeks — a net reduction of 10.9 percentage points (p=0.02), and the effect held to 26 weeks (net -12.7%, p=0.02). There was no significant change in non-HDL-C, VLDL-C, HDL-C, or LDL-C. This is a real, statistically significant, disease-population result — and it deserves to be reported as exactly that, not stretched further.
| Study | Population & n | Dose & duration | Result |
|---|---|---|---|
| Mozaffarian 2022 PMID 34989797 | Severe hypertriglyceridemia, n=520 (pooled TRILOGY 1+2) | 4g/day CaPre (krill-derived, pharmaceutical-track), 26 weeks | TG ↓26.0% vs ↓15.1% placebo at 12wk (net -10.9%, p=0.02); sustained to 26wk (net -12.7%, p=0.02) |
| Berge 2015 PMID 26666303 | Healthy young adults, n=17 (pilot) | 832.5mg EPA+DHA/day krill oil, 28 days | ↓ plasma triacylglycerol, large VLDL/chylomicron particles; ↑ n-6:n-3 ratio improvement |
Both industry-connected: Mozaffarian 2022/TRILOGY was funded and run by Acasti Pharma Inc. (CaPre's manufacturer), and a trial investigator served as the company's chief operating/strategy officer during the trial. Berge 2015 had multiple authors affiliated with Rimfrost AS, a krill oil manufacturer.
Why the dose and population gap matters so much here
It's tempting to read "krill oil lowered triglycerides 26% in a 520-person trial" and assume any krill oil product will do something similar. That's the exact overreach this page exists to prevent. The 4g/day CaPre dose delivers roughly 832-880mg of EPA+DHA-equivalent material — far above what any of the six retail krill oil products in this comparison deliver at their labeled 1-2 softgel serving (120-270mg EPA+DHA; see the product comparison). And TRILOGY's population had severe hypertriglyceridemia, a clinical state that responds differently to intervention than a general buyer's lipid panel. The smaller Berge 2015 pilot (n=17, healthy young adults, 832.5mg EPA+DHA/day for 28 days) is closer to a dose a highly motivated buyer could reach by taking several retail softgels — but it's a tiny, short, industry-affiliated pilot study, not confirmation that a standard serving works.
If your triglycerides are actually high
If you have a documented high triglyceride level, this evidence is a reason to talk to your doctor about omega-3 options generally — prescription-strength EPA/DHA agents are FDA-approved specifically for this and have outcomes data behind them — not a reason to self-treat with a retail krill oil softgel at a fraction of the studied dose. Severely elevated triglycerides carry a real pancreatitis risk and belong under clinical management. If your triglycerides are only mildly elevated, general omega-3 intake (from any source, at the general adequate-intake dose covered in the dosage guide) is a reasonable thing to discuss at your next visit, but it is not a substitute for medical follow-up if your levels are a documented concern.
Frequently asked questions
Does krill oil lower triglycerides?
TRILOGY (n=520) found a real 26.0% vs 15.1% placebo reduction at 12 weeks — but using a 4g/day pharmaceutical-track agent in severe hypertriglyceridemia, not a standard retail softgel.
Will a standard krill softgel replicate this result?
No. The dose (4g/day CaPre) and population (severe hypertriglyceridemia) are very different from a 1-2 softgel retail dose in a general buyer. Don't assume transfer.
Is this evidence industry-funded?
Yes — TRILOGY funded/run by Acasti Pharma (CaPre's manufacturer, with an investigator holding a company executive role); Berge 2015 authors affiliated with Rimfrost AS.
What triglyceride level needs a doctor, not a supplement?
Severe hypertriglyceridemia (the TRILOGY population) needs clinical management due to pancreatitis risk. Talk to a doctor rather than self-treating with any retail supplement.
Related
- Krill oil: what it is & who it's for
- Krill oil dosage guide — retail doses vs the pharmaceutical-track dose
- Best krill oil — ranked by disclosed EPA+DHA and cost
- Fish oil for triglycerides — the OTC-dose comparison
Sources
- Mozaffarian D, et al. "Effects of a Novel Omega-3 Phospholipid on Severe Hypertriglyceridemia (TRILOGY 1 and TRILOGY 2 Randomized Clinical Trials)." JAMA Netw Open. 2022. PMID: 34989797
- Berge K, et al. "Krill oil supplementation lowers serum triglycerides without increasing peroxidation markers." Lipids Health Dis. 2015. PMID: 26666303